ERBB2 and breast carcinoma: Initially, the goal of HER2 status assessment for breast cancer was to determine which patients with metastatic disease might benefit from treatment with trastuzumab (Herceptin: Genentech, San Francisco, CA, U.S.A.), the mono-clonal antibody to HER2, either alone or in combination with chemotherapy.